Fabtech Technologies Cleanrooms Ltd receives order in price ranges from Rs 49 crore to Rs 52 crore
DSIJ Intelligence-1 / 05 Nov 2025/ Categories: Mindshare, Trending

The stock is up by 40 per cent from its 52-week low of Rs 173.20 per share.
Fabtech Technologies Cleanrooms Limited has recevied a significant international order to build a Next-Generation Veterinary Formulations Facility in the North African Region. The order, which was received on November 3, 2025, was awarded by an upcoming veterinary manufacturing company whose name is being withheld due to confidentiality. This new facility is planned to be EU GMP certified, which will allow the customer to export veterinary products to the European Union and various neighbouring African countries.
The contract's value is estimated to range from Rs 49 crore to Rs 52 crore, exclusive of all applicable Taxes and levies, and the terms are based on standard industry conditions. This substantial project is expected to be completed and executed by the first quarter of 2027. This order represents a major international project for Fabtech Technologies Cleanrooms Limited in the growing North African pharmaceutical and veterinary sector.
About the Company
Fabtech Technologies Cleanrooms Limited, incorporated in 2015, is a global provider of specialised turnkey engineering solutions, primarily serving the pharmaceutical, biotech and healthcare industries. The company excels in the manufacturing and delivery of complete solutions for pre-engineered and pre-fabricated modular panels and doors designed for cleanrooms. Adhering to strict global regulatory standards like ISO and FDA, Fabtech's comprehensive offerings span from design and engineering through to manufacturing, quality assurance, installation and final validation for these critical infrastructure projects.
On Tuesday, Fabtech Technologies Cleanrooms Ltd gained 2.1 per cent Upper Circuit to Rs 242 per share from its previous closing of Rs 237 per share. The stock is up by 40 per cent from its 52-week low of Rs 173.20 per share.
Disclaimer: The article is for informational purposes only and not investment advice.